AbCellera Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	158.32	411.54	501.14	594.12	7.55	10.44
Short-Term Investments	627.27	499.95	246.84	0	0	0
Cash & Cash Equivalents	785.59	911.49	747.98	594.12	7.55	10.44
Cash Growth	-13.81%	21.86%	25.90%	7765.96%	-27.68%	-
Receivables	30.59	38.59	160.58	213.24	3.28	1.4
Other Current Assets	55.81	75.41	21.25	5.97	1.81	3.31
Total Current Assets	871.99	1,025	929.8	813.33	12.64	15.16
Property, Plant & Equipment	287.7	217.26	111.62	17.92	8.48	6.33
Long-Term Investments	65.94	72.52	50.31	19.25	1.78	0
Goodwill and Intangibles	168.23	179.31	196.2	146.65	0	0
Other Long-Term Assets	94.24	46.33	30.64	8.39	0.59	0
Total Long-Term Assets	616.11	515.42	388.77	192.21	10.85	6.33
Total Assets	1,488	1,541	1,319	1,006	23.49	21.49
Accounts Payable	104.97	112.76	90.41	56.49	2.58	1.57
Deferred Revenue	27.15	41.13	34.95	32.48	4.57	4.59
Current Debt	0	0	0	0	2.08	2.53
Other Current Liabilities	-13.11	-35.57	-4.68	14.52	-1.34	-2.26
Total Current Liabilities	119.01	118.32	120.68	103.49	7.9	6.43
Long-Term Debt	71.22	76.68	36.41	3.72	4.01	0.91
Other Long-Term Liabilities	145.54	112.64	135.75	67.82	1.34	2.54
Total Long-Term Liabilities	216.76	189.31	172.16	71.54	5.34	3.45
Total Liabilities	335.78	307.63	292.84	175.03	13.24	9.88
Total Debt	71.22	76.68	36.41	3.72	6.09	3.44
Debt Growth	-7.11%	110.57%	880.16%	-38.95%	76.76%	-
Retained Earnings	279.79	426.19	267.67	114.2	-4.72	-2.5
Comprehensive Income	-1.72	-1.39	0.28	0	0	0
Shareholders' Equity	1,152	1,233	1,026	830.51	10.25	11.61
Net Cash / Debt	714.36	834.81	711.56	590.4	1.47	7
Net Cash / Debt Growth	-14.43%	17.32%	20.52%	40118.05%	-79.03%	-
Net Cash Per Share	2.47	2.65	2.24	2.24	0.01	0.04
Working Capital	752.97	907.17	809.12	709.84	4.75	8.73
Book Value Per Share	3.98	4.33	3.72	5.22	0.07	0.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).